HIV: Update on Epidemiology and PrEP

Brigg Reilley
HIV/HCV National Programs
Brigg.Reilley@ihs.gov
New Cases of HIV, USA, AI/AN
(CDC surveillance, 2010-2014)

- Approximately 44,000 new cases/year in the USA
- HIV incidence among AI/AN patients has increased from 174 cases (7.9/100,000) in 2010 to 222 in 2014 (9.5/100,000)
- In 2014, an estimated 84% of new HIV cases were transmitted via sexual contact among Men Who Have Sex with Men (MSM)

Death rates

- AI/AN persons living with HIV/AIDS (PLWHA) have the lowest proportion of survival after 12, 24, and 36 months when compared to other age-matched groups
- Death rates from HIV among AI/AN about double Whites 1999-2008
- Late Diagnosis, poor linkage to care possible factors for change

Death Rates From Human Immunodeficiency Virus and Tuberculosis Among American Indians/Alaska Natives in the United States, 1990-2009

Main Transmission routes, Indian Country
(CDC AI/AN Fact sheet)
HIV Incidence, I/T/U, By sex

- Men about twice as likely as women to be diagnosed (Risk Ratio 2.2, 2.1-2.4)

- Men ages 20-49 about 3x more likely than age matched women to be diagnosed (RR 3.0, 2.3-3.7)

- Overall rate of new diagnoses increased 20% among males from 2010-2014
Prevention - Social Media

"I KNOW MY BODY. I KNOW MY STATUS."

"WE R NATIVE. WE R PROUD."
"WE ARE STD/HIV TESTED."
Prevention - HIV 101 Flip Chart

HIV Myths
Screening -
When is it the best course of action?

- Disease is often asymptomatic
- Early detection bestows benefits on patient (and community in infectious disease)
- Test is reliable, non-invasive, inexpensive
- *Screening does not replace risk-based testing/clinical judgment*
HIV Screening Recommendation

- HIV 13-64 GPRA measure as of 2016
- Prenatal HIV at over 90%, will be continue to be monitored
Milestones in HIV screening

- 1996 blood donors
- 2001 prenatal patients
- 2006 adolescents and adults

GPRA measure has also evolved
Screening is voluntary

- Inform patients orally or in writing (general medical consent) that HIV testing will be performed unless they decline.
- Arrange access to care, prevention, and support services for patients with positive HIV test results.
HIV Screening, best practices

- Facility level policy for HIV/STI testing and screening
- Clinical reminder in EHR
- Standing protocols
- Delegated away from provider
- Age-based targeting removes any stigma/judgment
HIV Screening, Cumulative, IHS Service Units, 2012-2016
HIV Screening Ever, Q2 2017, IHS facilities

All: 52%
Men 25-45: 42%
Figure 1. Proportion of Active Clinical Patients Tested for HIV, Cumulative, Southwest IHS Hospital, 2012-2016
ER, UC testing

- Positive result followed up by non ER clinician

- Can be paired with other high prevalence disease
  - STIs/urine ("cups by cuffs), HCV

- Can be tailored for feasibility
  - Only men ages 20-49
  - Only if blood being drawn for other reasons
HIV Screening - Recap

- Goal of new CDC recommendations to increase number who know HIV+ status
- People do not perceive risk
- Clinicians do not offer test
- Stigma more with “identified” risk and infection less so with testing itself
- Knowing HIV+ status can reduce transmission by:
  - Behavior change
  - Addressing Co-morbidity
  - Reducing viral load

MMWR 55:1-7, 2006
Inungu J. AIDS  Patient Care STDs 16:293, 2002
The **LINKAGES** Prevention, Care and Treatment Cascade

- Identify key populations
- Reach key populations
- Test key populations
- Diagnose PLHIV
- Enroll in care
- Initiate ART
- Sustain on ART
- Suppress viral loads

- Extend life
- Reduce transmission
What if there were a pill that could help prevent HIV?

There is.

Ask your doctor if PrEP is right for you.

Pre-exposure prophylaxis: A daily pill to reduce risk of HIV infection

www.cdc.gov/hiv/basics/prep.html
Epidemiology of New HIV Diagnoses
(Why is PrEP needed)
Lifetime Risk of an HIV Diagnosis by State
Overall: 1 in 99 (1.01%)

### Lifetime Risk* of an HIV Diagnosis

<table>
<thead>
<tr>
<th></th>
<th>MSM</th>
<th>Heterosexuals</th>
<th>PWID</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>All race/ethnicities</td>
<td>6</td>
<td>241</td>
<td>473</td>
</tr>
<tr>
<td>Black/African American</td>
<td>2</td>
<td>49</td>
<td>86</td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>4</td>
<td>242</td>
<td>390</td>
</tr>
<tr>
<td>Native Hawaiian/Pacific Islander</td>
<td>7</td>
<td>395</td>
<td>2,706</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>12</td>
<td>493</td>
<td>1,116</td>
</tr>
<tr>
<td>Asian</td>
<td>14</td>
<td>910</td>
<td>1,760</td>
</tr>
<tr>
<td>White</td>
<td>11</td>
<td>1,083</td>
<td>2,514</td>
</tr>
</tbody>
</table>

*From age 13 years  
What is PrEP? How well does it work?
What Is PrEP?

- Daily use of an antiretroviral pill for Pre-exposure prophylaxis (PrEP) is a highly effective method to reduce the risk of HIV infection.

- FDA approved a once-daily pill containing a fixed-dose combination of two antiretrovirals:
  - Tenofovir disoproxil fumarate (TDF) 300 mg
  - Emtricitabine (FTC) 200 mg

- Brand name is Truvada
How PrEP Works

Without PrEP, if a person is exposed to HIV, the virus will grow new copies of itself in the genital area and over 3-4 days will spread throughout the body.

With PrEP inside a persons cells, if they are exposed to HIV, the virus cannot grow. So HIV does not spread in the body and become an established HIV infection.
Daily Oral PrEP Effectiveness by Adherence in Initial Randomized Trials

PrEP Effectiveness and Adherence in Open-label and Observational Studies

- **MSM**
  - No HIV infections among men with protective drug levels

- **HIV discordant couples**
  - No infections among consistent PrEP users whose partners were not on ARVs for treatment

<table>
<thead>
<tr>
<th>Adherence by Drug Concentration</th>
<th>HIV Incidence per 100 PY</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 pills/week</td>
<td>4.7</td>
</tr>
<tr>
<td>&lt;2 pills/week</td>
<td>2.3</td>
</tr>
<tr>
<td>2-3 pills/week</td>
<td>0.6</td>
</tr>
<tr>
<td>≥4 pills/week</td>
<td>0.0</td>
</tr>
</tbody>
</table>
Common Provider Concerns about PrEP
(How safe is it?)
PrEP Side Effects and Safety

- **Start-up syndrome**
  - <10% with nausea, vomiting, cramps
  - Lasts a couple of weeks in most patients
  - Can be managed with over the counter medication

- **Renal safety**
  - Small decrease in creatinine clearance
  - Not clinically important
  - Returns to normal after PrEP use discontinued

- **Bone safety**
  - Small decrease in bone mineral density
  - Not associated with increased fractures
  - Returns to normal after PrEP use discontinued
Drug resistance in PrEP users who acquire HIV infection

- Most PrEP patients remain HIV-uninfected
  - No virus to develop resistance
- PrEP patients who stop taking their drug or take it infrequently have a risk of developing resistance or acquiring a drug-resistant virus from a partner
  - 2 cases of acquiring a multiple-drug resistant virus out of ~100,000 persons currently on PrEP
- PrEP patients who are fully adherent to daily dosing can (very rarely) acquire HIV infection
  - 1 case reported out of ~100,000 persons currently on PrEP
  - Virus had no drug resistance mutations
Primary Care Provider Issues
# PrEP Compares Favorably with Other High-Impact Preventive Measures

<table>
<thead>
<tr>
<th>Outcome to Prevent</th>
<th>Intervention</th>
<th>Number needed to treat to prevent one case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death from colorectal cancer</td>
<td>Annual fecal occult blood testing colorectal screen&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4551</td>
</tr>
<tr>
<td>Stroke in women with no previous CV disease</td>
<td>Aspirin 81 mg daily&lt;sup&gt;b&lt;/sup&gt;</td>
<td>411</td>
</tr>
<tr>
<td>Myocardial infarction in individuals with hypertension and average cholesterol</td>
<td>Atorvastatin 10 mg daily&lt;sup&gt;c&lt;/sup&gt;</td>
<td>100</td>
</tr>
<tr>
<td>HIV infection in MSM</td>
<td>TDF/FTC 1 pill daily&lt;sup&gt;d&lt;/sup&gt;</td>
<td>13</td>
</tr>
</tbody>
</table>

Primary Care PrEP Provision
(How do I do this?)
<table>
<thead>
<tr>
<th>Component</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk assessment</td>
<td>• PrEP is indicated for adult MSM, heterosexually-active women and men, and PWID who are at substantial risk for HIV infection through ongoing exposures</td>
</tr>
</tbody>
</table>
| Lab screen before prescribing | • HIV test, test for acute HIV infection if symptomatic  
• Adequate renal function (eCrCl ≥ 60 mL/min)                                             |
| Prescribing                   | • 1 daily TDF/FTC tablet (Truvada)  
• Prescribe no more than 90 day supply                                                        |
| Follow-up                     | • Test for HIV and pregnancy every 3 months  
• Test for sexually transmitted infections (STIs) every 6 months, even if asymptomatic  
• Counsel on risk reduction and medication adherence  
• Test creatinine clearance at 3 months and then every 6 months                                   |
| Discontinuation               | • At least every 12 months, assess risk behavior, medication adherence, and need for continuing PrEP use                                           |
# People at Substantial Risk of HIV Infection (Meet Indications for PrEP)

<table>
<thead>
<tr>
<th>MSM</th>
<th>Heterosexual Men and Women</th>
<th>PWID</th>
</tr>
</thead>
<tbody>
<tr>
<td>In the past 6 months:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• HIV-positive sexual partner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Bacterial STI  (esp. GC or syphilis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• More than one sex partner not known to have HIV infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Inconsistent or no condom use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Commercial sex work</td>
<td>In the past six months</td>
<td></td>
</tr>
<tr>
<td>• HIV-positive injecting partner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sharing injection equipment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In high-prevalence area
Examples of Brief Risk Assessment Questions

- Sexual risk
  - In the last year, how many sex partners have you had?
  - Did you have sex with men, women, or both?
  - Do you use condoms consistently?
  - Did any of your partners have HIV infection?

- Injection risk
  - Have you ever injected drugs that were not prescribed for you?
  - If yes...
  - When did you last inject drugs?
  - Do you ever inject using works that have been used by others before you?
Prescribing PrEP

At substantial risk

Support medication adherence

Prescribe PrEP

Normal renal function? (eCrCl)

Prescribe PrEP

Schedule follow-up visit within 3 months

Counsel about dosing and side effect management

If HIV infection confirmed: begin treatment test for resistance

Provide/refer for risk reduction services, e.g., medication-assisted treatment (MAT)

When indicated: Assess hepatitis B status, assess pregnancy status, STI testing

Clinical considerations: Comorbidities Medications
excluding acute or established HIV infection

HIV immunoassay blood test (rapid test if available)

Signs/symptoms of acute HIV infection

Preferred

Option 1
Retest antibody in one month
Defer PrEP decision

Option 2
Send blood for HIV antibody/antigen assay*

Option 3
Send blood for HIV-1 viral load (VL) assay

* Use only HIV antigen/antibody tests that are approved by FDA for diagnostic purposes

Supporting Medication Adherence

- Inform about any expected side effects and their management
  - Nausea, cramps, mild diarrhea in <10%
  - Resolves over 2-3 weeks
- Assess past issues with pill adherence
- Suggest adherence methods tailored to patient lifestyle and adherence history
  - Forget? Pill boxes, link to daily activity
  - Side effects? Take in before going to sleep
  - Away from home? Keep a pill or two with them
Retention in PrEP Care

Discontinuing PrEP

- For HIV seroconversion
  - Offer immediate transition to treatment regimen
  - Document HIV resistance test results

- For HIV negative persons
  - Document HIV and creatinine test results
  - Assure that HIV prevention plan is in place
  - If chronic hepatitis B infection, monitor liver function and if a flare occurs, treat in consultation with expert
Resources for Clinicians
(How can I get answers to my questions?)
PrEPline
(855) 448-7737 or (855) HIV-PrEP

Clinical advice available Monday-Friday 11:00 am to 6:00 pm EST

Voice mail available 24 hours a day. Typical response within 2 hours

- Clinical consultation staff
  - ID specialists
  - family physicians
  - clinical pharmacists
  - obstetricians
  - general internists
  - nurses

- Advice on
  - Initial and follow-up laboratory evaluation
  - Administering medications
  - Addressing adherence issues
  - Transitioning from PEP to PrEP
  - Managing PrEP for conception and pregnancy
### Additional Information

| **PrEPline (clinician telephone consultation)** | **855-448-7737 (855-HIV-PREP)**  
|                                               | http://nccc.ucsf.edu/clinical-resources/pep-resources/prep/ |
| **Truvada for PrEP Medication Assistance Program** | https://start.truvada.com/content/pdf/medication_assistance_program.pdf |
| **Gilead PrEP information for healthcare providers** | https://start.truvada.com/hcp# |
Resources for Patients
(What can I give my patients to aid them?)
Covering the Cost of PrEP

- Insurance
- Medicare
- Patient Assistance Programs
  - Consider highlighting AI/AN status in application
PrEP Uptake and Impact
(Does this really make a difference?)
## Estimated percentages and numbers of adults with indications for preexposure prophylaxis (PrEP), by transmission risk group — United States, 2015

<table>
<thead>
<tr>
<th>Transmission Risk Group</th>
<th>% with PrEP indications*</th>
<th>Estimated no.</th>
<th>(95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men who have sex with men, aged 18–59 yrs</td>
<td>24.7</td>
<td>492,000</td>
<td>(212,000–772,000)</td>
</tr>
<tr>
<td>Adults who inject drugs, aged ≥18 yrs</td>
<td>18.5</td>
<td>115,000</td>
<td>(45,000–185,000)</td>
</tr>
<tr>
<td>Heterosexually active adults, aged 18–59 yrs</td>
<td>0.4</td>
<td>624,000</td>
<td>(404,000–846,000)</td>
</tr>
<tr>
<td>Men</td>
<td>0.2</td>
<td>157,000</td>
<td>(62,000–252,000)</td>
</tr>
<tr>
<td>Women</td>
<td>0.6</td>
<td>468,000</td>
<td>(274,000–662,000)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>—</td>
<td><strong>1,232,000</strong></td>
<td>(661,000–1,803,000)</td>
</tr>
</tbody>
</table>

**Abbreviation:** CI = confidence interval.

* Percentage of all estimated persons in each transmission risk group and demographic subset with PrEP indications.

Unique Individuals Starting FTC/TDF for PrEP in US, 2012 to 2015 (by quarter)

79,684 unique individuals started FTC/TDF for PrEP:

1,671 in Q4 2012 → 14,000 in Q4 2015

738% increase
New HIV diagnoses and deaths in people living with HIV, San Francisco, 2006-2014

FDA approves Truvada for PrEP
Billing Code Examples

- **CPT codes**
  - 99385 New preventive visit (20 minutes), 18-39 yo
  - 99395 Established preventive visit (15 minutes)
  - 99401 Risk factor counseling visit (15 minutes)
  - HIV and other tests ordered, venipuncture (36415)

- **ICD 9-CM codes**
  - V01.79 Contact with other viral diseases (HIV)
  - V69.2 High risk sexual behavior
  - V07.9 Unspecified prophylactic measure
  - Codes for specific STIs, IDU, or pregnancy
In Sum

- Prevention options available for your facility
- Risk based testing and screening, especially men 25-49 important for early detection
- Linkage to care available
- PrEP is an effective new tool
- Support for PrEP available
- More information also available on related topics that were not covered in this presentation (substitution therapy, etc.)